PDS Biotechnology Receives Nasdaq Delisting Notice for Minimum Bid Price Non-Compliance
PDSB is trading near its 52-week low of $0.601 (14% above the low) on light trading volume (0.2× avg).
Summary
PDS Biotechnology Corp received a Nasdaq deficiency notice for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period to avoid potential delisting.
Key Events · Corporate Governance and Compliance · PDSB
-
Nasdaq Deficiency Notice Received
PDS Biotechnology Corp was notified on February 25, 2026, that its common stock fell below Nasdaq's $1.00 minimum bid price requirement for 30 consecutive business days.
-
180-Day Compliance Period Initiated
The company has until August 24, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
-
Potential Delisting Risk
Failure to meet the minimum bid price requirement by the end of the compliance period could result in the delisting of the company's common stock from The Nasdaq Capital Market.
-
Reverse Stock Split Under Consideration
The company stated it may consider a reverse stock split as an option to regain compliance with the Nasdaq listing rules.
Analysis · PDSB · Life Sciences
This 8-K filing officially discloses that PDS Biotechnology has received a Nasdaq deficiency notice due to its common stock trading below the $1.00 minimum bid price for 30 consecutive business days. While the company has 180 calendar days to regain compliance, failure to do so could lead to delisting from The Nasdaq Capital Market. The company is considering options, including a reverse stock split, which often signals distress and can be viewed negatively by investors. This event poses a significant risk to the company's liquidity and investor confidence, as continued listing on Nasdaq is crucial for a micro-cap company.
At the time of this filing, PDSB was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.6M. The 52-week trading range was $0.60 to $1.92. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.